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Abstract
ADIPOQ, encoding adiponectin, is a candidate gene for type 2 diabetes (T2D) identified by genome-wide linkage analyses
with supporting evidence showing the protein function in sensitizing insulin actions. In an endeavor to characterize
candidate genes causing T2D in Thai patients, we identified 10 novel ADIPOQ variations, several of which were non-
synonymous variations observed only in the patients. To examine the impact of these non-synonymous variations on
adiponectin structure and biochemical characteristics, we conducted a structural analysis of the wild-type and variant
proteins by in silico modeling and further characterized biochemical properties of the variants with predicted structural
abnormalities from the modeling by molecular and biochemical studies. The recombinant plasmids containing wild-type
and variant ADIPOQ cDNAs derived from the variations identified by our study (R55H, R112H, and R131H) and previous work
(G90S and R112C) were constructed and transiently expressed and co-expressed in cultured HEK293T cells to investigate
their oligomerization, interaction, and secretion. We found that the novel R55H variant impaired protein multimerization
but it did not exert the effect over the co-expressed wild-type protein while novel R131H variant impaired protein secretion
and also affected the co-expressed wild-type protein in a dominant negative fashion. The R131H variant could traffic from
the endoplasmic reticulum to the Golgi, trans-Golgi network, and early endosome but could not be secreted. The R131H
variant was likely to be degraded through the lysosomal system and inhibition of its degradation rescued the variant
protein from secretion defect. We have shown the possibility of using in silico modeling for predicting the effect of amino
acid substitution on adiponectin oligomerization. This is also the first report that demonstrates a dominant negative effect
of the R131H variant on protein secretion and the possibility of using protein degradation inhibitors as therapeutic agents in
the patients carrying adiponectin variants with secretion defect.
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Introduction
Type 2 diabetes (T2D) is a multifactorial disorder in which the
interactions between susceptible genetic and particular environ-
mental factors are attributable to its pathogenesis. After the
breakthrough of microarray technologies, several T2D-predis-
posing genetic variations have been identified by a genome-wide
association study (GWAS), following the concept of common
disease-common variant (CDCV) hypothesis [1]. However, it has
now been realized that those common variations conferred a
small risk and most of their pathogenic effects are elusive. The
trend in searching for genetic components of T2D is thus shifted
towards the common disease-rare variant (CDRV) hypothesis [2].
The rare variants with risk can be detected by exome [3] or
whole genome sequencing [4] but the methods based on
candidate gene analysis are still practical in terms of their
simplicity and cost effectiveness.
ADIPOQ, encoding adiponectin, is a candidate gene for T2D as
evidenced from both genome-wide linkage and its biological
functions in sensitizing insulin actions. This gene is located on
chromosome 3q27, the region where the gene responsible for T2D
was mapped [5,6]. Adiponectin is exclusively secreted from
adipose tissue as three classes of oligomeric forms, including
trimers, hexamers and high molecular weight (HMW) multimers
[7]. Adiponectin is classified as a member of adipocytokines that
facilitates insulin actions in peripheral tissues by activating AMP
kinase and p38 MAPK [8–10]. Each adiponectin oligomer exerts
distinct levels of insulin sensitizing effects and HMW multimer is
the major active form of adiponectin [7,11,12].
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26792Although none of GWAS has revealed ADIPOQ as T2D
susceptible locus, the role of ADIPOQ in T2D development cannot
be excluded since ADIPOQ rare variants were not probed by those
studies. Various common ADIPOQ variants have been reported to
be associated with plasma adiponectin levels, but none of them
was consistently associated with T2D [13,14]. By contrast, rare
adiponectin variants leading to oligomerization and secretion
defects have been found to be associated with hypoadiponectine-
mia and diabetic phenotypes [15]. It has been suggested that rare
functional variants may have stronger effects than the slight
changes in adiponectin levels induced by common variants [14].
We are interested in identifying functional ADIPOQ variants in
Thai patients with T2D. Many novel variations were identified
and interestingly several variations resulted in amino acid
substitutions in adiponectin proteins. To initially predict the effect
of these amino acid changes on the protein structure, we employed
in silico modeling and mutagenesis for analysis to compare the
structures of wild-type and variant adiponectins. Then, the wild-
type and variant adiponectins with predicted structural abnormal-
ities were further studied by molecular cloning and protein
expression in cultured cells. The expressed proteins were analyzed
for their oligomerization, interaction, and secretion. In addition,
sub-cellular localization, degradation pathway and inhibition of
the variant proteins were investigated. The results of this study will
provide more insight into the molecular defect of adiponectin
underlying T2D pathogenesis and a potential therapeutic
approach based on a targeted molecule and specific molecular
mechanism.
Results
Identification of ADIPOQ variations
A total of 18 variations (Figure 1 and Table S1) were identified
in the studied subjects (Table 1). Ten of them are novel (Figure S1,
NCBI SS#: 120239896–120239900 and 120246102–120246106).
Five rare non-synonymous variations resulted in amino acid
substitutions including R55H, R112H, R221S, R131H and
H241P (Figure 2A). R55H, R131H, H241P, and two other
variations (211388G.A and P25P) were not observed in 210
non-diabetic controls, suggesting their roles in the development of
T2D. By using computational analyses, 211388G.A is not
located in any consensus sequence of transcription factor binding
sites and P25P resided in neither cryptic splice site nor exonic
splicing enhancer (ESE) (data not shown). Therefore, these two
variations were not explored further in this study. Since non-
synonymous variations are more likely to cause the disease, they
were focused on in this study.
Amino acid substitutions, structural alterations and
oligomerization of adiponectin
Seven adiponectin variants identified in other ethnic groups
including G84R, G90S, Y111H, R112C, I164T, R221S, and
H241P were previously characterized for their effect on protein
oligomerization (Table 1) [15]. We analyzed all the reported
variants and those identified in our study by amino acid sequence
alignment (Figures 2B and 2C). It was observed that substitutions
in the highly conserved amino acids (G84R, G90S, R112C, and
I164T) affect protein oligomerization (Table 1) whereas substitu-
tions at the less conserved positions (Y111H, R221S, and H241P)
do not disturb formation of adiponectin oligomers (Table 1).
However, the analyses of local structural alterations attributable to
these amino acid substitutions in relation to their molecular defects
by in silico modeling have not previously been conducted. To
analyze this relationship, we compared the molecular structures of
the previously reported variants and those identified in our study
with that of the wild-type protein by in silico modeling and
mutagenesis.
The G84R and G90S variants are located in the collagenous
domain (Figure 2A). To date, the crystal structure of adiponectin
collageneous domain is unavailable. Therefore, the 3D structure of
these two variants could not be analyzed. However, they reside in
Gly-X-Y repeats, the highly conserved region which is important
for triple helix formation and forming of higher degree of
adiponectin oligomers. Substitutions of glycine with either arginine
(G84R) or serine (G90S) cause the decrease in Gly-X-Y repeated
numbers and impaired adiponectin multimerization [15]. Only
the crystal structure of mouse adiponectin globular domain is
available [16]. We therefore created a structure of human
adiponectin globular domain (Figure 3) by homology modeling
using a 30 kD adipocyte complement-related protein precursor –
ACRP30 (PDB 1C28), the most suitable template identified by
blast searches, as a template. The alignments of mouse template
(residues 114–245) and human (residues 111–242) globular
domain sequences showed 97.91% of sequence identity without
any gaps. The superimpositions of template and all human
adiponectin variants showed the root mean square (RMS) values
of 0.89 A ˚, 0.67 A ˚, and 0.57 A ˚ for chain A, B, and C, respectively.
Figure 1. ADIPOQ structure. Three boxes represent 3 exons of ADIPOQ. The coding regions are indicated as filled boxes. The positions of 18
variations identified in this study are located. The variations in upper panel are novel and those in the lower panel were reported. The variations
which were indentified in the patients with T2D but not in non-diabetic individuals are indicated with asterisks.
doi:10.1371/journal.pone.0026792.g001
Novel Adiponectin Variants and T2D
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adiponectin oligomeric classes and exhibited secretion defects
(Table 1), showed the alteration of the trimer interface. R112C
was likely to cause loss of H-bonds between monomers (Figure 4A).
The introduction of the hydroxyl group of threonine (T) instead of
the hydrophobic side chain of isoleucine (I) at residue 164 was
likely to disturb the hyprophobic core within adiponectin
monomers (Figure 4C). The correlation between the in silico
analysis performed in this study, and the results from previous in
vitro experiments, suggests the potentiality in the use of amino acid
alignment together with in silico mutagenesis for prediction of the
effect of amino acid substitutions on adiponectin oligomerization.
In the present study, three novel adiponectin variants including
R55H, R112H, and R131H were identified (Figure 2A). Arginine
at residues 55 (Figure 2B) and 131 (Figure 2C) are conserved
among all available species and the R55H and R131H variants
were identified only in T2D patients but not non-diabetic controls.
R55 resides in the highly conserved Gly-X-Y motif in the
collagenous domain; thus, it was speculated to affect the formation
of adiponectin HMW multimers, the same as was observed for the
G84R and G90S variants. In silico modeling of R131H revealed
the alteration of H-bond forming patterns within the globular
domain (Figure 4B). Therefore, we hypothesized that R131H
might impair adiponectin oligomerization and secretion, the same
as that demonstrated for R112C and I164T. R112H was identified
in a non-diabetic individual but not T2D patients. In addition,
amino acid residue 112 in the sequence alignment can be either
arginine (R) or histidine (H) (Figure 2C). Therefore, R112H was
speculated to exhibit normal protein oligomerization.
Expression, secretion, and oligomerization of novel
adiponectin variants
In order to investigate the impact of the three novel adiponectin
variants (R55H, R112H, and R131H) on protein oligomerization
and secretion, the recombinant proteins of these three novel and
the other two reported variants, G90S and R112C, which
exhibited multimerization and secretion defects [15], respectively,
were transiently expressed in cultured HEK293T cells. The
expression, secretion, and oligomerization of these variants were
investigated. All variants could be expressed (Figure 5A); however,
R112C and R131H variants were undetectable in culturing media
(Figure 5B). Under non-reducing and non heat-denaturing
conditions, adiponectin wild-type and R112H variant clearly
exhibited three oligomeric forms (Figure 5C). In contrast, small
amounts of HMW of R55H and G90S variants were detected both
in cell lysate (Figure 5C) and in culturing media (Figure 5D). In cell
lysate, R112C variant exhibited protein aggregation while R131H
variant showed combined patterns of protein aggregation and
abnormal oligomerization (Figure 5C), which were correlated with
secretion defect.
Since all variants identified in the studied subjects were in
heterozygous conditions, co-expression of wild-type and adipo-
nectin variants was carried out to determine whether the variant
proteins have any effect on the wild-type protein or not. The
cDNA sequence encoding wild-type protein was tagged with either
c-Myc or FLAG sequence while all of those encoding variant
proteins (R55H, G90S, R112C and R131H) were tagged with
FLAG sequence.
Under the conventional SDS-PAGE, both cell lysate and
culturing media of HEK293T cells expressing wild-type protein
alone and those co-expressing wild-type proteins and either R55H
or G90S variant exhibited the similar protein levels when they
were detected with either anti-Myc (Figures 6A and 6B) or anti-
FLAG (Figures 6E and 6F) antibody. Under non-reducing and
non-heat denaturing conditions, HMW multimers of the wild-type
protein co-expressed with either R55H or G90S could be detected
at the same levels as the wild-type protein when it was expressed
alone (Figures 6C and 6D). However, HMW multimers of the
variant proteins were barely detected (Figures 6G and 6H). These
results suggested that the formation of wild-type HMW multimers
was not interfered by the R55H and G90S variants which are
defective in multimerization.
In cell lysate, the level of wild-type protein expressed alone and
wild-type proteins co-expressed with either R112C or R131H
variant were similarly detected by conventional SDS-PAGE
(Figure 6A). The levels of R112C and R131H variants were
similar to that of the wild-type protein when they were detected by
anti-FLAG antibody (Figure 6E). However, in culturing media, the
wild-type proteins when co-expressed with either the R112C or
R131H variant was present at lower levels as it was compared to
that of the wild-type protein expressed alone (Figure 6B),
suggesting that the two variant proteins could induce the wild-
Table 1. Amino acid substitutions in collagenous and globular domains of adiponectins and their effects.
Amino acid residue Formation of oligomer Phenotype
Domain Human Other species
Amino acid
substitution
Effect on local
structure Trimer Hexamer HMW Diabetes
Hypoadipone-
ctinemia Population
Collagenous R55 R R55H ND Yes Yes No Yes ND Thai
G84 G G84R ND Yes Yes No Yes Yes Japanese [33], French [34]
G90 G G90S ND Yes Yes No Yes Yes French [34]
Globular Y111 Y and H Y111H ND Yes Yes Yes Yes Yes French [34]
R112 R and H R112C Yes No No No Yes Yes Japanese [35]
R112H ND No No No No ND Thai
R131 R R131H Yes No No No Yes ND Thai
I164 I and L I164T Yes No No No Yes Yes Japanese [35], Japanese [33]
R221 R, S, H, N, and V R221S ND Yes Yes Yes No No Japanese [35], Japanese [33], Thai
H241 H and P H241P ND Yes Yes Yes No No Japanese [35], Japanese [33], Thai
ND stands for not determined.
doi:10.1371/journal.pone.0026792.t001
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R131H variants were slightly present in culturing media
(Figure 6F), suggesting that the lower amounts of variant proteins
could be secreted when they were co-expressed with wild-type
protein. Under non-reducing and non-heat denaturing conditions,
wild-type protein co-expressed with either R112C or R131H in
cell lysate were found to be aggregated (Figure 6C) and lower
amounts of their HMW multimers were observed in culturing
media, as compared to those of wild-type expressed alone
(Figure 6D). Thus, the R112C and R131H variants could exert
a dominant negative effect over the wild-type protein, causing the
secretion defect of the wild-type protein by sequestering into their
co-aggregated forms. All oligomeric forms (and some aggregated
forms) of R112C and R131H variants were detected in cell lysate
(Figure 6G), suggesting that some hetero-oligomers between the
wild-type and variant proteins could be formed. In addition, low
levels of these hetero-oligomers could be secreted in culturing
media (Figures 6F and 6H).
Sub-cellular localization of wild type and variant adiponectins
It has been reported that a substantial amount of adiponectin in
the steady state of 3T3-L1 adipocytes was located in the Golgi/
TGN [17] and it was released via the endosomal compartment
[18]. To examine the intracellular trafficking underlying the
secretion defects of adiponectin variants, HEK293T cells were
transfected with the plasmid constructs containing either wild-type
or variant (R112C and R131H) cDNA tagged with the FLAG
sequence to observe their expression and localization with the
intracellular organelle markers. These included Calnexin, Giantin,
TGN46, and an early endosome antigen 1 (EEA1) which are the
organelle markers for endoplasmic reticulum (ER), Golgi appara-
tus, trans-Golgi network and early endosome, respectively. The
results showed that wild-type and variant (R112C and R131H)
adiponectins were similarly co-localized with all organelle markers
studied (Figure 7). The localizing coefficients and co-localizing
intensities of the two variants and all organelles were not different
from those of the wild type proteins (data not shown).
Figure 2. Adiponectin protein structure and amino acid alignment. A: Adiponectin protein is divided in to signal sequence, variable region,
collageneous domain and globular domain. The upper panel indicates variants identified in this study. Those identified only in T2D patients are
indicated with asterisks. The lower panel represents the variants that have been previously reported. B and C: Multiple alignments of adiponectin
protein from different species using BioEdit Sequence Alignment Editor. The positions of amino acid substitutions are located. B: Variations located in
collageneous domain. C: Variations located in globular domain.
doi:10.1371/journal.pone.0026792.g002
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Generally, misfolded and unassembled proteins in ER are
transported to be degraded via the proteasomal system in
cytoplasm. However, the non-secreted R112C and R131H
variants could traffic from ER through Golgi, trans-Golgi network,
and early endosome (Figures 7A–7D). Thus, we hypothesized that
the lysosomal system should be the site for their degradations. To
test our hypothesis, the levels of intracellular and secretory forms
of wild-type protein, R112C and R131H variants in the presence
of proteasomal/lysosomal and lysosomal inhibitors were exam-
ined. In the presence of MG132 – a proteasome inhibitor which
also inhibits lysosomal cysteine proteases, the intracellular level of
Figure 3. Three dimensional structure of modeled human adiponectin globular domain and positions of amino acid variations.
Human adiponectin was constructed by homology modeling using mouse adiponectin [16] as a template. Each monomer of the adiponectin trimer
structure is shown in different color. The positions of amino acids being substituted are indicated with arrows.
doi:10.1371/journal.pone.0026792.g003
Figure 4. Local structural alterations of amino acid substitutions (R112C, R131H, and I164T) in modeled human adiponectin
globular domain. Wild-type and variant adiponectin trimer are superimposed. Three monomers of adiponectin wild-type are indicated in green,
cyan, and magenta and labeled with the color letters corresponding to their chain. The variant residues are showed with the gray sticks and labeled
with the black letters. The side chains of amino acids within hydrophobic core are shown in line structure with surrounding dots. The O, N, and S
atoms are shown with red, blue, and yellow, respectively. A–C: The local structural alterations for R112C, R131H, and I164T variants, respectively.
doi:10.1371/journal.pone.0026792.g004
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(Figure 8A). This was correlated with the finding that its secretion
was promoted by this inhibitor (Figure 8D). Brefeldin A (BFA) – an
antibiotic that inhibits transport of proteins from ER to Golgi and
induces retrograde protein transport from the Golgi to the ER,
significantly increased the intracellular level of wild-type protein
by abatement of its secretion (Figures 8A and 8D). Inhibition of
lysosomal hydrolase activity by NH4Cl and chloroquine signifi-
cantly increased the intracellular level of wild-type protein
(Figure 8A) by diminishing its secretion (Figure 8D) rather than
reducing its degradation. In contrast, MG132 increased both
intracellular and extracellular levels of R112C (Figures 8B and 8E)
and R131H variants (Figures 8C and 8F), suggesting that
inhibition of proteasomal and lysosomal activities by MG132
could decrease their degradation while promoting their secretion.
After holding proteins within ER by BFA, the intracellular levels of
these two variants were significantly increased. These results
suggested that chemical retention of variant proteins, within the
ER, rescued proteins from degradation. Thereby, post-ER
organelles are likely responsible for their degradation. The finding
that NH4Cl and chloroquine significantly increased intracellular
levels of R112C and R131H variants confirmed the role of
lysosome in degradation of these two variants. Additionally,
inhibitions of lysosomal degradation by NH4Cl and chloroquine
could also promote secretion of the two adiponectin variants
(Figures 8E and 8F). Taken together, these results suggested the
role of the lysosomal compartment in the turnover of R112C and
R131H variants, but not the wild-type protein.
Discussion
Herein, we reported novel adiponectin variants identified in
Thai patients with T2D and demonstrated the effects of amino
acid substitutions on structural alterations and the defects in their
biochemical properties. The novel R55H and R131H variants
were likely to be implicated in T2D pathogenesis by affecting
adiponectin multimerization and secretion, respectively. Since the
patients who carried these two variants had taken anti-hypergly-
cemic drugs that affect plasma adiponectin levels, the plasma
adiponectin levels in these patients were not measured. The
decreased adiponectin levels in these patients were suspected as
implied from the observation that the novel R55H and R131H
variants exhibited the same characteristics as the reported G90S
and R112C variants, respectively, which were found to be
associated with hypoadiponectinemia [15] (Table 1). It should
be noted that the patients who carried these two novel variants
exhibited greater waist circumferences than the average value of
the patients with T2D (Table 2), pointing out the clinical
characteristics that associate with adiponectin abnormalities.
These variants were found among T2D patients, but not in a
sample of non-diabetic subjects. Collapsing these two functional
variants together for analysis did not show significant association
with T2D (p.0.05, data not shown). Additionally, an association
between these variants and T2D cannot be determined with
certainty because of the low power associated with the small
sample size and the low frequencies of these variants.
The adiponectin collagenous domain is crucial for stabilizing of
adiponectin trimers and further formations of hexamers and
HMW multimers via interdisulfide bonds [19]. The R55H, G84R,
and G90S variations did not disturb adiponectin trimeric and
hexameric formations but obstructed their multimerization. These
variants are not close to interdisulfide bond forming site (Cys
36)
and they were still capable of forming hexamers. However, they
might cause conformational change and conceal the remaining
free thiol from interacting with other hexamers. Another possible
mechanism responsible for multimerization defect might be due to
ineffectiveness of these variants in interacting with ER chaperones,
such as ERp44 [20] or Ero1-a [21], which assist the formation of
adiponectin multimers. It is remarkable that molecular sizes of the
R55H and G90S variants were higher than that of the wild-type,
implying a gain-of-glycosylation which has been reported as a
characteristic of rare mutations implicated in several diseases [22].
However, whether R55H and G90S are gain-of-glycosylation
variants, and exactly what is the precise mechanism responsible for
their multimerization defects, are still to be elucidated.
Adiponectin globular domain is crucial for initiation of trimer
formation through hydrophobic interaction. Variations occurred
at the globular domain may impair adiponectin trimerization
Figure 5. Expression, secretion, and oligomerization of adiponectin variants. Cell lysate (A) and culturing media (B) of HEK293T cells
transiently expressed adiponectin wild-type and variants under reducing and heat-denaturing condition. Cell lysate (C) and culturing media (D) of
HEK293T cells transiently expressed adiponectin wild-type and variants under non-reducing and non heat-denaturing condition. The total protein of
each sample was equally loaded. Results shown are typical of three independent experiments.
doi:10.1371/journal.pone.0026792.g005
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R112C and I164T [15] as well as the novel R131H variants. We
found that protein aggregation exhibited by the R112C and
R131H variants disappeared in the presence of a reducing agent
(data not shown). These findings suggested disulfide-linked
aggregation of these two variants. Generally, protein folding is
determined by hydrophobic interactions and hydrogen bonding.
The breaking of H-bonds between R112C monomers and the
alteration of H-bond forming patterns within R131H monomers,
as suggested by in silico modeling and mutagenesis, may obstruct
the formation of adiponectin trimers. The resulting free thiol may
cause incorrect disulfide cross-linking that participates in protein
aggregation [23].
While the R55H and G90S variants did not interfere with wild-
type protein in the forming of HMW multimers, we showed that
the R112C and R131H variants could form aggregated complexes
with the wild-type protein, resulting in decreasing wild-type
protein secretion. However, some forms of hetero-oligomers
between the wild-type and mutant proteins could be secreted
from the cultured HEK293T cells. These secreted hetero-
oligomers might be predominated with the wild-type protein.
It is known that proteasomal and lysosomal systems are the two
major pathways for intracellular degradation of the misfolded and
unassembled proteins. Abnormal proteins, which are destined to
proteasomal degradation, are usually retained within ER before
being degraded by the proteasome pathway. However, the R112C
Figure 6. Co-expression of wild-type and variant adiponectins. Adiponectin variants tagged with FLAG sequence were co-expressed with
wild-type tagged with c-Myc sequence. A–D: Immunoblotting of wild-type protein by using anti-Myc antibody. E–H: Immunoblotting of variant
proteins by using anti-FLAG antibody. A, B, E and F: Cell lysates (A and E) and culturing media (B and F) of adiponectin variants co-expressed with
wild-type under reducing and heat-denaturing condition. C, D, G, and H: Cell lysate (C and G) and culturing media (D and H) of adiponectin variants
co-expressed with wild-type under non-reducing and non heat-denaturing condition. The total protein of each sample was equally loaded. Results
shown are typical of three independent experiments.
doi:10.1371/journal.pone.0026792.g006
Novel Adiponectin Variants and T2D
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they trafficked to Golgi, TGN, and even endosomes but could not
be secreted. Therefore, we hypothesized that the lysosomal system
should play a role in the degradation of these two variants. The
increases of both intracellular and extracellular levels of these two
variants in the presence of lysosomal inhibitors supported our
hypothesis. Nonetheless, the increase in intracellular levels of wild-
type proteins by lysosomal inhibitors was probably attributable to
a decrease in its secretion, rather than prevention from its
degradation. Consistent with this study, Blumer et al. have
demonstrated that the acidotropic agents inhibited secretion of
endogenous adiponectin from adipocytes by interrupting an acidic
interior of vesicular pathway and showed that the lysosomal
system was not responsible for degradation of endogenous (or wild-
type) adiponectin [24]. It is possible that misfolded or unassembled
variants, but not wild-type adiponectin, are degraded by the
lysosomal system, and inactivation of lysosomal compartments
allows these abnormal proteins to escape from the degradation
system to be secreted into the culturing media.
We have shown that inhibition of protein degradation by
MG132 could promote secretion of the R112C, R131H, and
wild-type adiponectins. In the same way, MG-132 treatment of
mdx mice rescued the expression and membrane localization of
dystrophin, the protein which is absent in the skeletal muscle of
Duchenne muscular dystrophy (DMD) patients and mdx mice
[25]. This finding is also similar to the increased secretion of the
mutant Z form of a1-antitrypsin (a1-AT) which is responsible for
greater than 95% of individuals with a1-AT deficiency syndrome
by inhibition of intracellular degradation using proteasomal
inhibitors [26]. In addition, proteasome inhibitions also increased
Figure 7. Sub-cellular localizations of wild-type, R112C and R131H adiponectins. The wild-type, R112C and R131H adiponectins linked
with FLAG epitope transiently expressed in HEK293T cells were detected with mouse anti-FLAG antibody, and with either rabbit anti-Calnexcin (A),
rabbit anti-Giantin (B), rabbit anti-TGN46 (C) or rabbit anti-EEA1 (D) antibody, which are antibodies specific to ER, Golgi, TGN and early endosome
markers, respectively. Goat anti-mouse IgG-conjugated with Alexa FluorH 488 (green) and donkey anti-rabbit IgG-conjugated with Cy3 (red) were
secondary antibodies for staining adiponectin and the organelle markers, respectively. The nucleus was stained with Hoechst 33342 fluorescent dye
(blue).
doi:10.1371/journal.pone.0026792.g007
Novel Adiponectin Variants and T2D
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production of toxic peptide accumulation in the brain of
Alzheimer patients [27]. In most of the cases, it is likely that
inhibition of proteasome activities decreases the opportunity of
misfolded proteins retained in ER to be degraded, thereby
prolonging their time in the ER lumen, and increasing the chance
to be retrieved by vesicular trafficking. However, the R112C and
R131H variants can traffic from ER to Golgi, trans-Golgi
network, and early endosome but can not be secreted, and the
lysosomal, rather than proteasomal, system is responsible for their
degradations. Thus, MG132 may rescue their secretion by other
mechanisms. One possibility is that MG132 elevates a number of
ER chaperones necessary for protein folding [28]. There is
evidence indicating that misfolded proteins can be refolded
successfully by modifying the molecular chaperone environment
using proteasome inhibitors, including MG132 [29,30]. For
example, enzymatic function of a cystathionine b-synthase (CBS)
variant, T262M, could be rescued by MG132 and was not
associated with increased levels of CBS T262M variant. It has
also been shown that the rescuing effect of MG132 was
accompanied by elevation of Hsp70 chaperone content but was
not due to inhibition of mutant protein degradation [30]. Thus, it
is likely that MG132 may promote secretion of the R112C
and R131H variants through its effect on molecular chaperones
in ER.
In summary, we have identified novel candidate variants for
T2D in the ADIPOQ gene in the Thai population. R55H variant
impairs protein mutimerization while the novel R131H variant
causes secretion defect in a dominant negative fashion. We have
also demonstrated that secretion defect is unlikely to result from
retention of the variant proteins in ER and the lysosomal
compartment plays a role in degradation of these variants. We
have also illustrated that MG132 can enhance wild-type protein
secretion and rescue adiponectin variants from secretion defect.
This suggests the benefit of using protease inhibitors or other
compounds that modify the chaperone environment in ER as
therapeutic agents for the treatment of patients carrying
adiponectin variants with secretion defect.
Figure 8. Investigation of lysosomal degradation of wild-type, R112C and R131H adiponectins. At 24 hours after transfection, HEK293T
cells were treated with proteasomal/lysosomal or lysosomal inhibitors for 8 hours. The concentrations of reagents are as followed: MG132 10 mM,
BFA 5 mg/mL, NH4Cl 25 mM and chloroquine (CHQ) 100 mM. Equal amount of protein from each sample was immunoblotted with anti-FLAG. A–C:
Intracellular adiponectin levels of wild-type (A), R112C (B) and R131H (C) after treating with degradation inhibitors. The bar graphs represented
relative levels of adiponectin (adiponectin/actin) represented in folds of samples treated with DMSO. Data are mean 6 SD of 3 independent
experiments. * P value,0.05, analyzed by Mann-Whitney U test. D–F: Extracellular adiponectin levels of wild-type (D), R112C (E) and R131H (F) after
treating with degradation inhibitors. Results shown are typical of 3 independent experiments.
doi:10.1371/journal.pone.0026792.g008
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Subjects and assessment of clinical data
A total of 272 of T2D subjects were recruited at Siriraj Hospital
Diabetic Clinic. The criteria for diagnosis of diabetes mellitus
followed that were described by the American Diabetes Associ-
ation (ADA) 1997. With this sample size, we had 93.4%
probability of detecting mutations with a frequency in the T2D
population as low as 0.5% and 99.6% probability to detect
mutations with a frequency as low as 1%. Ethical approval for the
study was granted by the Ethics Committee of the Faculty of
Medicine Siriraj Hospital. All subjects were informed for the
purpose and extent of the study before signing consent forms and
enrollment into the study. The patients’ plasma glucose was
determined by glucose oxidase method. Glycosylated hemoglobin
(HbA1C), total cholesterol, triglycerides, and HDL-cholesterol
were assayed by standard procedures. LDL-cholesterol was
calculated by Friedewald formula or measured directly when
appropriate. A number of 210 non-diabetic controls were
volunteers recruited at Siriraj Hospital Check-up Center,
Department of Preventive and Social Medicine, Faculty of
Medicine Siriraj Hospital, Mahidol University. The selection
criteria included healthy individuals with (i) age more than 40
years, (ii) fasting plasma glucose levels less than 100 mg/dl, and (iii)
no family history of diabetes in their first degree relatives.
Analyses of ADIPOQ gene
DNA samples were extracted from EDTA anti-coagulated venous
blood samples by a standard phenol/chloroform method. Regula-
tory region (11.5–10.33 kb upstream of the start codon), 59
untranslated region, exon-intron boundaries, and coding regions of
ADIPOQ were analyzed for sequence variations by polymerase chain
reaction andsinglestrand conformation polymorphism(PCR-SSCP)
method, followed by direct sequencing. The details of primers and
optimal PCR-SSCP conditions are provided in Table S2.
In silico investigation of rare non-synonymous variants
The three dimensional structure of both wild-type and variant
human adiponectin were constructed by homology modeling using
the SWISS-MODEL workspace [31]. The modeling steps
included: (i) identification of the most suitable template, (ii)
alignment of target sequence and template structure, (iii) model
building, and (iv) model quality evaluation. Alterations of H-bond
forming pattern caused by variant proteins were examined on
PyMOL (DeLano Scientific LLC, CA, USA).
Plasmid construction, transfection, and preparation of
samples for analysis
ADIPOQ coding region (NM_004797.2) with either the FLAG
(DYKDDDDK) or c-Myc (EQKLISEEDL) tagged sequences at
the carboxyl terminus was generated from a human kidney cDNA
library using the primers exhibited in Table S3 and cloned into
pcDNA3.1(+), between BamHI and EcoRI sites. Plasmid constructs
containing each of three novel variants (R55H, R112H, and
R131H) and two previously reported ones (G90S and R112C) [15]
were generated by PCR site-directed mutagenesis using the wild-
type adiponectin tagged with FLAG as a template. The plasmid
constructs were transfected into HEK293T cells cultured in
DMEM/F-12 supplemented with 10% FBS by using Lipofecta-
mine 2000 (Invitrogen, CA, USA). Cells were harvested at
48 hours after transfection. Cell lysate was prepared using RIPA
buffer (1% NP-40, 0.5% deoxycholate, 0.1% SDS, 150 mM NaCl,
20 mM Tris-HCl pH 7.4, 5 mM EDTA pH 8.0), supplemented
with protease inhibitor cocktail (Roach Diagnotics GmbH,
Mannheim, DE). The culturing media was cleared by centrifuga-
tion at 13,500 rpm for 1 hour, and dialyzed against distilled water
for 24 hours before concentrating by lyophilization. The lyoph-
ilized media was dissolved with a low salt buffer (20 mM HEPES,
1 mM CaCl2). Total protein contents in prepared samples were
quantified by Bradford protein assay.
Table 2. Clinical and laboratory characteristics of studies subjects.
T2D carrying non-synonymous variant
Clinical and laboratory parameter T2D Non-diabetic control p value R55H* R131H H241P
Number (male/female) 202 (58/144) 210 (58/147) - 2 (0/2) 1 (1/0) 1 (0/1)
Age (year) 53.75 6 11 53.34 6 9.06 NS 65 55 59
Age at diagnosis (year) 49.39 6 10.87 - - 65 53 53
Weight (kg) 68.58 6 12.47 59.08 6 9.83 ,0.001 70 84.7 69
BMI (kg/m
2) 27.84 6 4.95 23.85 6 3.2 ,0.001 27.24 27.66 27.64
Waist (cm) 87.99 6 10.9 82.24 6 9.29 ,0.001 92 100 86
Hip (cm) 99.82 6 9.73 95.68 6 6.69 ,0.001 110 105 94
Waist/hip ratio 0.89 6 0.07 0.86 6 0.06 ,0.001 0.84 0.95 0.91
Systolic BP (mm Hg) 132.146 16.16 115.5 6 14.04 ,0.001 120 140 200
Diastolic BP (mm Hg) 81.43 6 10.4 70.94 6 9.35 ,0.001 70 74 110
FPG (mmol/L) 11.33 6 5.1 4.88 6 0.35 ,0.001 18.93 5.77 10.93
HbA1c (%) 8.29 6 2.49 - - 12 7.4 10.1
Total cholesterol (mmol/L) 5.86 6 1.2 5.46 6 0.94 ,0.001 5.96 3.08 5.80
Triglyceride (mmol/L) 2.02 6 1.02 1.17 6 0.49 ,0.001 1.41 1.21 2.16
LDL-C (mmol/L) 3.71 6 1.08 3.23 6 0.86 ,0.001 4.43 1.18 3.68
HDL (mmol/L) 1.27 6 0.31 1.59 6 0.42 ,0.001 1.06 1.35 1.14
Data are mean 6SD. The p values compare clinical and laboratory data between 202 of T2D patients whose data are completely available and 210 non-diabetic controls
by using either Mann–Whitney U or student’s T-test.
*Data of one from two patients carrying R55H.
doi:10.1371/journal.pone.0026792.t002
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Cell lysate and culturing media were prepared for SDS-PAGE
as described by Waki et al [15]. For investigation of protein
expression and secretion, samples were heated in the presence of
b-mercaptoethanol before being separated by 12% SDS-PAGE.
Their multimerizations were investigated by using 2–12% gradient
SDS-PAGE under non-reducing and non-heat denaturing condi-
tion [15]. Proteins were transferred to the nitrocellulose mem-
brane and then blocked with 3% skim milk in TBS-T before
incubating with either anti-FLAGH M2 Monoclonal antibody
(Sigma, MO, USA), c-Myc antibody (Santa Cruz Biotechnology,
CA, USA), or anti-actin antibody (Santa Cruz Biotechnology, CA,
USA) diluted in TBS-T containing 3% skim milk. After washing,
the membrane was incubated with the HRP-conjugated secondary
antibody (Dako, Glostrup, Denmark), and visualized with the
enhanced chemiluminescence (ECL) system (Promega, WI, USA).
Relative quantities of the proteins were determined by using the
ImageJ program [32].
Immunofluorescent staining and co-localization analysis
HEK293T cells were grown on glass coverslips overnight,
before transfection with plasmid constructs containing wild-type or
variant (R112C or R131H) adiponectin cDNA tagged with FLAG
sequence. At 24 hours after transfection, cells were fixed in 2%
paraformaldehyde in PBS, permeabilized by 0.2% Tritron-X in
PBS, washed with 1% FBS in PBS, and immunostained with
mouse anti-FLAGH M2 Monoclonal antibody for adiponectin and
either rabbit anti-Calnexin (Santa Cruz Biotechnology, CA, USA),
rabbit anti-Giantin (Abcam, Cambridge, UK), rabbit anti-TGN46
(Abcam, Cambridge, UK) or rabbit anti-EEA1 (Abcam, Cam-
bridge, UK) antibodies diluted in 1% FBS in PBS for 1 hour. After
discarding the primary antibodies, cells were washed with 1% FBS
in PBS before incubating with secondary antibodies conjugated
with fluorescent dye for another 1 hour. Each secondary antibody
mixture contained Alexa FluorH 488-conjugated goat anti-mouse
(Molecular Probes, Eugene, USA), Cy3-conjugated donkey anti-
rabbit IgG (Jackson Immunoresearch Laboratories, West Grove,
USA), and Hoechst 33342 dye (Invitrogen, Carlsbad, USA) for the
staining of recombinant adiponectin, organelle markers, and
nuclei, respectively. The coverslips were washed with 1% FBS in
PBS and then mounted with 50% antifade reagent. The
immunofluorescent images were examined and captured by
confocal laser scanning microscope (Zeiss LSM 510 META).
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